|
Age at inclusion, y, median (IQR)
|
18.7 (17.9–20.2)
|
|
Male sex, n (%)
|
4 (40)
|
|
Age at diagnosis, m, median (IQR)
|
6.9 (0.1–11.4)
|
|
Mutation of ATP1A3
|
|
p.D801N
|
5 (50)
|
|
Other mutations
|
5 (50)
|
|
Total paroxysmal events per week
|
|
Median (IQR)
|
3.88 (3.19–4.85)
|
|
Mean (SD)
|
4.39 (1.95)
|
|
Chronic medications, n (%)
|
9 (90)
|
|
Number, median (IQR)
|
3 (3–4)
|
|
Flunarizine, n (%)
|
8 (80)
|
|
Acetazolamide, n (%)
|
2 (20)
|
|
Permanent neurologic deficiency
|
|
Pyramidal syndrome
|
8 (80)
|
|
Cerebellar syndrome
|
8 (80)
|
|
Dystonia
|
8 (80)
|
|
Cognitive/ behavioral dysfunction
|
6 (60)
|
